MetaCap

Acurx Pharmaceuticals (ACXP) vs Kyntra Bio (KYNB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kyntra Bio is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACXP-20.00%KYNB-74.55%
+4%-37%-78%
Oct 7, 20261 yearNov 20, 2026
ACXP-18.11%KYNB-74.47%
+4%-37%-78%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACXP versus KYNB key metrics
MetricACXPKYNB
Share price$1.04$1.56
Market cap$6.30M$6.32M
1-day change+0.97%-13.33%
YTD return—-82.23%
1-year return—-81.47%
5-year return—-99.49%
EPS (TTM)$-1.90$-4.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.44M
Revenue growth (YoY)—-78.26%
Net income (latest FY)$-7.97M$183.45M
Gross margin—91.37%
Operating margin—-712.66%
Net margin—2848.63%
52-week high$7.54$10.47
52-week low$0.90$1.56
Distance from 52-week high-86.21%-85.10%
Analyst consensusstrong_buynone
Avg. price target upside+1534.62%+2442.95%
Average volume97.29K29.96K
Shares outstanding6.06M4.05M
Employees434
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Acurx Pharmaceuticals

ACXP stock →

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Kyntra Bio

KYNB stock →

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

ACXP vs KYNB FAQ

Which is bigger, Acurx Pharmaceuticals or Kyntra Bio?

Kyntra Bio (KYNB) is larger, with a market capitalization of $6.32M compared with $6.30M for Acurx Pharmaceuticals (ACXP).

Are Acurx Pharmaceuticals and Kyntra Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons